Cladribine (Mavenclad®)

Assessment Status NCPE Assessment process complete
HTA ID -
Drug Cladribine
Brand Mavenclad®
Indication For the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features
Assessment Process
Rapid review outcome A Full pharmacoeconomic assessment is recommended
Preliminary review sent to Applicant 09/02/2018
NCPE assessment re-commenced 02/03/2018
Factual accuracy sent to Applicant 18/06/2018
NCPE assessment re-commenced 02/07/2018
NCPE assessment completed 20/07/2018
NCPE assessment outcome Following NCPE assessment of the company submission, cladribine (Mavenclad®) is considered cost-effective for the treatment of adult patients with highly active relapsing MS as defined by clinical or imaging features and therefore is recommended for reimbursement.

The HSE has approved reimbursement following confidential price negotiations September 2018.

Technical Summary